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The method for chemical modification of spergualin with retention of the configuration at the C-1I has been achieved by the use of tetrahydropyranyl group for protection of the 11-hydroxyl group. (-)-15-Deoxyspergualin
(2), which shows about eight times stronger inhibition against mouse leukemia L-1210 than the natural (-)-spergualin
(1), and (-)-spergualin-15-phosphate (3) possessing a good antitumor activity have been synthesized starting from 1.
In our studies on new antitumor antibiotics, spergualin was discovered in culture filtrates of a bacterial strain BMG162-aF2 which is related to Bacillus laterosporus, and the structure was determined by us to be (-)-(15S)-1-amino-]9-guanidine-11,15-dihydroxy-4,9,12-triazanonadecane-10,13-dione.1,2)
But, only the C-11 stereochemistry remained undefined. The total synthesis was accomplished by the acid-catalyzed condensation of 11-amino-l,l-dihydroxy-3,8-diazaundecan-2-one (a hydrate of glyoxylylspermidine) with 7-guanidino-3-hydroxyheptanamide followed by the separation of the 11-epimeric mixture.3) Antibacterial or antitumor activity of the epimeric mixture of spergualin was about a half of that of the natural (-)-spergualin.4 It suggests that the C-11 stereochemistry plays a role in the biological action of spergualin.
Therefore, in addition to the synthesis of spergualin and its related compounds by the acid-catalyzed condensation, we studied the method for the derivation of (-)-spergualin (1) with retention of the configuration at C-11. A facile method has been achieved for protection of the 11-hydroxyl group by the use of tetrahydropyranyl group. In this paper, we report the synthesis of (-)-15-deoxyspergualin (2) and (-)-spergualin-15-phosphate (3). was retained during protection and deprotection of the amine and hydroxyl groups, since deprotection of N-benzyloxycarbonyl and O-tetrahydro-pyranyl groups in 5 by catalytic hydrogenation and mild acid hydrolysis as described later gave the optically pure 1.
Treatment of compound 5 with methanesulfonyl chloride in anhydrous pyridine afforded a mesylate 6 in 54% yield. Halogenation of 6 with sodium iodide in anhydrous N,N-dimethylformamide followed by hydrogenation with a palladium catalyst gave (-)-15-deoxy-ll-O-tetrahydropyranylspergualin
in 18 % yield. The tetrahydropyranyl group of 7 (trihydrochloride) was hydrolyzed with one tenth molar amount of p-toluenesulfonic acid in water under ice-cooling for 7 hours to yield levorotatory (-)-15-deoxyspergualin (2) in 78 % yield. Compound 2 was about eight times more potent than 1 against mouse leukemia L-1210, as shown in Table 1 . The acute LD50 of 2 trihydrochloride to mice by intravenous or intraperitoneal injection was 35 -40 mg/kg.
Phosphorylation of 5 with diphenyl phosphorochloridate in anhydrous pyridine afforded the 15-diphenyl phosphate (8) in 53 % yield. Hydrogenation of 8 with a platinum catalyst (48% yield) followed by mild hydrolysis of 9 with p-toluenesulfonic acid in water (62% yield) gave (-)-spergualin-l5-phosphate (3). Compound 3 showed about half the antitumor activity compared with 1 (Table 1) .
(-)-11-O-Tetrahydropyranylspergualin (10) prepared by catalytic hydrogenation of 5 was almost inactive against mouse leukemia L-1210 in the dose range of 0.78-25 mg/kg/day, intraperitoneally.
The daily administration of 12.5 mg/kg or more caused death of mice. 105 cells/CDF1 mouse i.p., administration: i.p. daily from day 1 to day 9, evaluation: at day 60, prolongation rate (T/C, %): mean survival period of treated/mean survival period of controls. Experimental General All compounds described in this paper did not show definite melting points.
Optical rotations were measured with a Perkin-Elmer 241 polarimeter.
The 1H NMR spectra were recorded with Varian XL-100 and EM-390 spectrometers. The chemical shifts in CD3OD or D2O refer to an external standard of tetramethylsilane (b=0), TLC was performed on a plate of Silica gel 60 (E. Merck) developed with a mixture (3: 2: 2: 1) of 1-butanol, pyridine, water and acetic acid; zones were detected by ninhydrin spray; spergualin showed Rf 0.13. Antibacterial activities were determined by the cylinder-plate method against Bacillus subtilis PCI219 with pure spergualin trihydrochloride as the assay standard. (-)-1-N,4-Bis(benzyloxycarbonyl)-11-O-tetrahydropyranylspergualin (5) To a solution of 4 hydrochloride (3.45 g, 4.81 mmole) in N,N-dimethylformamide (30 ml) was added 3,4-dihydro-2H-pyran (0.63 ml, 9.75 mmole) and p-toluenesulfonic acid hydrate (464 mg, 2.44 mmole) and the solution was stirred for 7 hours at room temperature. The reaction mixture was treated with triethylamine (0.33 ml, 2.44 mmole) and concentrated to dryness. Fraction Nos. 85 -92 were combined and concentrated to recover 4 as the acetate salt (362 mg, 10%).
( _)-1-N,4-Bis(benzyloxyca_rbonyl)-15-O-methanesulfonyl-11-O-tetrahydropyranylspergualin (6) To a solution of 5 (acetate, 950 mg, 1.13 mmole) in anhydrous pyridine (10 ml) was added methanesulfonyl chloride (0.13 ml, 1.74 mmole) under ice-cooling. After stirring for 3 hours, water (0.2 ml) was added to the solution and the solution was concentrated to give a syrup. The syrup was purified by column chromatography of silica gel (Wakogel C-200, 100 g) with a mixture (320: 40: 4: 1) of chloroform, methanol, pyridine and 50% aqueous acetic acid to give 6 as the acetate salt (598 mg, 54%).
O-15-Deoxy-11-O-tetrahydropyranylspergualin (7) To a solution of 6 (acetate, 591 mg, 0.699 mmole) in anhydrous N,N-dimethylformamide was added Nat (5.02 g, 33.5 rnmole). After stirring at 90°C for 15 hours, the solution was concentrated to dryness. The residue was dissolved in ethyl acetate (30 ml). The solution was washed with 20%. aqueous Na2-S2O3 solution (30 ml) and saturated-NaCl solution (30 ml), successively. The organic layer was dried over anhydrous Na2SO, and concentrated to give a syrup. The syrup was purified by column chromatography of silica gel (Wakogel C-200, 50 g) with a mixture (320: 40: 4: 1) of chloroform, methanol, pyridine and 50% aqueous acetic acid (10-m1 fractions). Fractions (Nos. 7-28) were combined and concentrated to give a 15-iodo derivative as the acetate salt (204 mg, 33 %).
The 15-iodo derivative (acetate, 198 mg, 0.214 mmole) in 80 % aqueous methanol (20 ml) was hydrogenated with 5 % palladium on BaCO, (40 mg) under a hydrogen stream at atmospheric pressure for 10 hours at room temperature.
The catalyst was removed by filtration and the filtrate was concentrated to give a syrup. The syrup was dissolved in 0.1m NaCl (30 ml) and the solution was adjusted to pH 6.5 with I M HCl. The product in the solution was adsorbed on a column of CM-Sephadex C-25 (40 ml, equilibrated with 0.1 M NaCl) and eluted with a linear gradient of 0.1 M to 0.8 M NaC1 (each 200 ml). The eluate was cut into 4-ml fractions. Fractions (Nos. 67 -77) were combined and concentrated to dryness. The residue was extracted with methanol (5 ml x 3). The product in the methanol solution was purified by a column of Sephadex LH-20 (100 ml) eluted with 90% aqueous methanol (1-ml fractions). Fractions (Nos. 36-.47) were combined and concentrated to give a colorless syrup of 7 trihydrochloride (62.9 mg, 54 % from the 15-iodo derivative), [al26D -16° (c 1, water), 1H NMR (CD3OD) S 3.7-4.1 (tetrahydropyranyl 6-CH2, m), 5.56 (11-CH, s).
(-)-15-Deoxyspergualin (2) To a solution of 7 (trihydrochloride, 61 mg, 0.112 mmole) in water (3 ml) was added p-toluenesulfonic acid hydrate (2.1 mg, 0.011 mmole) under ice-cooling. After stirring for 7 hours, the solution was adjusted to pH 6.5 with 1 M NH,OH and added 0.4 M NaCl (10 nil). Compound 2 in the solution was adsorbed on a column of CM-Sephadex C-25 (25 nil, equilibrated with 0.4 M NaCl) and eluted with a linear gradient of 0.4 M to 1.0 M NaCI (each 100 ml). The eluate was cut into 2-ml fractions. Fractions (Nos. 73 ' 81) were combined and concentrated to dryness. The residue was extracted with methanol (5 ml x 3). Compound 2 in the methanol solution was purified by a column of Sephadex LH-20 (100 ml) eluted with 90% aqueous methanol (1-ml fractions). Fractions (Nos. 38-48) were combined and concentrated to give a colorless syrup of 2 trihydrochloride (46.6 mg, 78;0), [a] ;'-7.3° (c 1, water), 1H NMR (D20) 1 1.7-2.3 (CH, x 6, m), 2.5-2.9(2-CH2 and 14-CH2, m), 3.5 -3.9 (NCH2 x 5, m), 5. (-)-1-N,4-Bis(benzyloxycarbonyl)-11-O-tetrahydropyranylspergualin-l5-diphenyl phosphate (8) To a solution of 5 (acetate, 663 mg, 0.786 mmole) in anhydrous pyridine (10 ml) was added diphenyl phosphorochloridate (0.34 ml, 1.63 mmole) under ice-cooling and the mixture was stirred for 4 hours. After addition of water (0.5 ml), the reaction mixture was concentrated to dryness. A solution of the residue in ethyl acetate (20 ml) was washed with water (20 ml). The organic layer was dried over anhydrous Na,SO, and concentrated to give a syrup. The syrup was purified by column chromatography of silica gel (Wakogel C-200, 50 g) developed with a mixture (320: 40: 4: 1) of chloroform, methanol, pyridine and 50% aqueous acetic acid (10-m1 fractions). Fractions (Nos. 30'91) were combined and concentrated to give a colorless syrup of 8 as the acetate salt (437 mg, 51 %), 1H NMR (CD3OD) 6 3.7-4.1 (tetrahydropyranyl 6-CH2, m), 5.04 and 5.08 (benzyl CH2, s), 5.3 (15-CH, m), 7.20 and 7.31 (10H, aromatic).
(-)-l I-O-Tetrahydropyranylspergualin-l5-phosphate (9) Compound 8 (acetate, 435 mg, 0.415 mmole) in 80%. aqueous methanol (10 ml) was hydrogenated with Pt02 catalyst (30 mg) under a hydrogen stream at atmospheric pressure for 7 hours at room temperature. The catalyst was removed by filtration and the filtrate was concentrated to dryness. The residue was dissolved in 0.1 M NaCI (20 ml) and the solution was adjusted to pH 6.4 with 1 M HCl. The product in the solution was adsorbed on a column of CM-Sephadex C-25 (20 ml, equilibrated with 0.1 M NaCl) and eluted with a linear gradient of 0.1 M to 1.0 M NaCl (each 100 ml). The eluate was cut into 2-ml fractions. Fractions (Nos. 36 " 44) were combined and concentrated to dryness. The residue was extracted with methanol (5 ml >: 3). The product in the methanol solution was purified by a column of Sephadex LH-20 (100 ml) eluted with 90°%o aqueous methanol (I-ml fractions). Fractions (Nos. 38' 45) were combined and concentrated to give a colorless syrup of 9 trihydrochloride (128 mg, 48%), 1H NMR (CD,OD) 5 3.8-.4.2 (tetrahydropyranyl 6-CH2, m), 5.2 (15-CH, m).
(-)-Spergualin-15-phosphate
To a solution of 9 trihydrochloride (112 mg, 0.175 mmole) in water (5 nil) was added p-toluenesulfonic acid hydrate (3.3 mg, 0.017 mmole) under ice-cooling.
After stirring for 8 hours, the solution was adjusted to pH 6.5 with 1 M NH4OH and added 0.4 M NaCl (20 ml). Compound 3 in the solution was adsorbed on a column of CM-Sephadex C-25 (20 ml, equilibrated with 0.4 M NaCl) and eluted with a linear gradient of 0.4 M to 1.0m NaCI (each 100 ml). The eluate was cut into 2-ml fractions.
Fractions were combined and concentrated to dryness. The residue was extracted with methanol (5 ml x 3). Compound 3 in the methanol solution was purified by a column of Sephadex LH-20 (100 ml) eluted with 90 aqueous methanol (I-ml fractions). Fractions (Nos. 41 -52) were combined and concentrated to give a colorless syrup of 3 as the salt (67.7 mg, 62°,,), [a] (-)-11-O-Tetrahydropyranylspergualin (10) Compound 5 (acetate, 100 mg, 0.119 mmole) in 90% aqueous methanol (5 ml) was hydrogenated with 5 % palladium on BaCO3 (10 mg) under a hydrogen stream at atmospheric pressure for 3 hours at room temperature. The catalyst was removed by filtration and the solution was concentrated to give a syrup. The syrup was dissolved in 0.4 M NaCl (20 ml) and the solution was adjusted to pH 6.5 with I M HCl. The product in the solution was adsorbed on a column of CM-Sephadex C-25 (20 ml, equilibrated with 0.4 M NaCl) and eluted with a linear gradient of 0.4 M to 1.0 M NaCI (each 100 ml). The eluate was cut into 2-ml fractions. Fractions (Nos. 37-49) were combined and concentrated to dryness. The residue was extracted with methanol (5 ml x 3). The product in the methanol solution was purified by a column of Sephadex LH-20 (100 ml) eluted with 90% aqueous methanol (1-ml fractions). Fractions (Nos. 48 -59) were combined and concentrated to give a colorless syrup of 10 trihydrochloride (46 mg, 65 %), [a]D -21° (c 3, water), IH NMR(CD3OD) 5 3.7-4.1 (tetrahydropyranyl 6-CH2, m), 5.67 (11-CH, s), antibacterial activity, 7% of 1.
Anal. Calcd. for C22H45N705.3HCl: C 44.26, H 8.10, N 16.42, Cl 17.81. Found : C 44.43, H 8.21, N 16.20, Cl 18.13 . Deprotection of (-)-11-O-tetrahydropyranylspergualin (10) By the similar method described in the synthesis of 2, 10 (trihydrochloride, 50 mg, 0.089 mmole) was hydrolyzed with p-toluenesulfonic acid hydrate (1.7 mg, 0.009 mmole) in water (1 ml) under icecooling for 7 hours. After adjusting to pH 6.5 with 1 M NH4OH, 0.4 M NaCI (5 ml) was added to the solution. The product in the solution was adsorbed on a column of CM-Sephadex C-25 (10 ml, equilibrated with 0.4 M NaCl) and eluted with a linear gradient of 0.4 M to 1.0 M NaCl (each 50 ml, 1-ml fractions). Fraction Nos. 43 -51 were combined and concentrated to dryness. After extraction with methanol (2 nil x 3), the extract was passed through a column of Sephadex LH-20 (100 ml) and eluted with 90% aqueous methanol (1-ml fractions). Fraction Nos. 3946 were combined and concentrated to give a colorless syrup of 1 trihydrochloride (29 mg, 64%), [a]D26-11° (c 2, water).
